Dual Antiplatelet Therapy (DAPT) in 2022


The three objectives of this talk were to

  1. Develop critical appraisal skills for the DAPT evidence base
  2. Review and understand techniques for evidence synthesis of this evidence base
  3. Appreciate the role and limitations of professional society guideline processes

My take home messages from this presentation were;

  1. For acute coronary syndromes, there is inconclusive evidence for any net clinical superiority between different DAPT regimes, but big cost differences do exist
  2. For stable CAD, no evidence for net clinical benefit with DAPT over ASA alone
  3. DAPT duration, awaiting more evidence that shorter duration provides equivalent benefit, but may be considered for those at very high bleeding risk
  4. Current CCS guideline recommendations needs revisiting

Feb 3, 2022 8:00 AM — 9:00 AM
St. Mary’s Hospital Department of Medicine Grand Rounds
St. Mary’s Hospital
Montreal, QC
Professor of Medicine & Epidemiology

I am a tenured (full) professor with a joint appointment in the Departments of Medicine and Epidemiology and Biostatistics where I work as a clinical cardiologist and do research in cardiovascular epidemiology.